UBX – unity biotechnology, inc. (US:NASDAQ)
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan [TechCrunch]
Unity Biotechnology, Inc. (NASDAQ: UBX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $6.00 price target on the stock.
UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com